Welcome to our dedicated page for Tecogen SEC filings (Ticker: TGEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Searching Tecogen鈥檚 disclosures usually means wading through technical CHP diagrams and detailed emissions data. Investors want the revenue split between product sales and long-term service, or need to confirm when executives file Form 4 insider transactions before major project wins. This page maps every SEC release to the exact question you are asking鈥攚hether it鈥檚 backlog growth or R&D spending鈥攕o you no longer have to hunt through dense footnotes.
Type a phrase like 鈥淭ecogen quarterly earnings report 10-Q filing鈥� or 鈥淭ecogen proxy statement executive compensation鈥� and Stock Titan returns the document plus an AI-powered summary that highlights segment margins, new clean-energy incentives, and board pay packages. AG真人官方-time alerts push Tecogen Form 4 insider transactions the moment they hit EDGAR, letting you track executive stock moves without refreshing your browser. Need context? Our expert engine links related 8-Ks, turning 鈥淭ecogen 8-K material events explained鈥� into a concise timeline of project awards, financing rounds, or patent milestones.
Because Tecogen鈥檚 business blends equipment sales with recurring service revenue, understanding cash-flow nuances is critical. Our coverage spans every form鈥攆rom the 鈥淭ecogen annual report 10-K simplified鈥� that dissects backlog trends, to bite-size analytics for each 鈥淭ecogen earnings report filing analysis.鈥� Use AI plain-language explanations to compare quarter-over-quarter growth, monitor compliance with clean-air regulations, and flag subsidy disclosures. In short, this hub is your fastest route to understanding Tecogen SEC documents with AI鈥攁ll filings, all the time, always current.
Form 4 filing synopsis: Tecogen Inc. (TGEN) director Earl R. Lewis was granted 25,000 non-qualified stock options on 07/24/2025 at an exercise price of $8.35 per share. The award vests 25 % each year and carries a 10-year term, expiring 07/24/2035. No common shares were bought or sold and no cash changed hands at the time of grant.
After this transaction, Lewis holds 91,250 derivative securities (options) in total, all recorded as direct ownership. The filing represents routine equity compensation aimed at aligning the director鈥檚 incentives with long-term shareholder value. Because the transaction involves options rather than immediate share issuance, near-term cash flow and ownership percentages are unaffected; any dilution would occur only if the options are exercised in the future.
Tecogen Inc. (TGEN) Form 4: On 07/24/2025, director Angelina Galiteva was granted a non-qualified stock option for 25,000 shares of common stock at an exercise price of $8.35. The option vests 25 % annually and expires on 07/25/2035. No shares were sold or otherwise disposed of in this filing. Following the grant, Galiteva鈥檚 total derivative holdings stand at 225,000 option-linked shares. The filing, dated 07/28/2025, shows the transaction was made in a direct ownership capacity; there is no indication of indirect ownership or group filing. No non-derivative transactions were reported.
Tecogen (TGEN) filed an 8-K announcing governance and compensation changes dated 24 Jul 2025. The board has split the CEO and CFO/Treasurer roles; CEO Dr. Abinand Rangesh resigned as CFO/Treasurer and remains CEO & director. Roger P. Deschenes, CAO since Sept 2020 and former division CFO at L3, was appointed CFO, Principal Financial Officer and Treasurer while retaining his CAO duties, a move intended to strengthen internal controls.
Compensation adjustments: the committee raised Deschenes鈥� salary to $180k and granted equity worth 鈮�$200k (17,964 restricted shares plus 12,063 ISOs, 25 % annual vesting). Rangesh received 鈮�$600k in equity (53,892 RSAs, 24,075 ISOs, 12,048 NQ options). General Counsel John K. Whiting IV and VP Business Development Stephen Lafaille each received 鈮�$200k in equity and salary increases to $180k. All options are priced at the 24 Jul 2025 NYSE American close.
The board also authorized Dr. Rangesh to grant up to $200k in options to non-executive employees. A press release confirming Deschenes鈥� appointment was issued 28 Jul 2025 (Exhibit 99.1). No financial performance data were disclosed.
On 21 Jul 2025, Tecogen Inc. (TGEN) filed an 8-K announcing the closing of a firm-commitment underwritten public offering of 3,985,000 common shares (incl. 485,000 overallotment) at $5.00 per share. Gross proceeds equal roughly $19.9 million; after underwriting discounts and estimated expenses, net proceeds are about $18.16 million.
Roth Capital Partners served as sole manager and underwriter. Management intends to allocate the cash to product development, expanded sales & marketing, additional staffing, capital expenditures, and working capital as the company pursues entry into the data-center market. Exhibit 99.1 contains a related press release, furnished but not deemed filed under the Exchange Act.
FAQ
What is the current stock price of Tecogen (TGEN)?
What is the market cap of Tecogen (TGEN)?
